CN109608519A - A kind of cell-penetrating peptide and its application - Google Patents
A kind of cell-penetrating peptide and its application Download PDFInfo
- Publication number
- CN109608519A CN109608519A CN201811312090.2A CN201811312090A CN109608519A CN 109608519 A CN109608519 A CN 109608519A CN 201811312090 A CN201811312090 A CN 201811312090A CN 109608519 A CN109608519 A CN 109608519A
- Authority
- CN
- China
- Prior art keywords
- cell
- penetrating peptide
- adriablastina
- mediated
- culture medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The present invention provides a kind of cell-penetrating peptide, the amino acid sequence of the cell-penetrating peptide are as follows: Arg-Arg-Lys-Lys-Trp-Trp.The cell-penetrating peptide can mediated adriablastina be delivered in cell.The nontoxic non-immunogenicity of cell-penetrating peptide of the invention.And Solid-phase synthesis peptides technology maturation, it is cheap and easy to get, it is managed convenient for quality.
Description
Technical field
The invention belongs to field of biotechnology, and in particular to a kind of cell-penetrating peptide and the cell-penetrating peptide are delivered in mediated adriablastina
In application.
Background technique
Adriamycin is a kind of broad-spectrum anti-tumor antibiotic, can inhibit the synthesis of tumour cell RNA and DNA, in various
The tumour cell of growth cycle has killing effect.Because adriamycin has very high cost performance, global adriamycin medicine in 2015
Object sales volume just reaches 8.1 hundred million dollars.However to still remain solubility small for adriamycin, delivery efficiency is low and the equal system of organ toxicity
Column problem, therefore the delivery system of adriamycin and means are all in urgent need to be improved.
Cell-penetrating peptide (cell-penetrating peptides, CPPs), abbreviation cell-penetrating peptide are that one kind can efficiently be taken
The small peptide for entering cell with macromolecular substances is widely used in the design of new bio nano material.Part cell-penetrating peptide is certain
Classical encytosis can not depended on and realize direct delivering, at the same can be designed again by artificial sequence have both targeting and
It is non-toxic.So in delivery process by cell-penetrating peptide mediate it is direct deliver be optimal.
Summary of the invention
In order to solve the problems in the existing technology, the present invention provides a kind of cell-penetrating peptide, which can be efficient
Mediated adriablastina is delivered into the cell.
The present invention provides a kind of cell-penetrating peptide, the amino acid sequence of the cell-penetrating peptide are as follows: Arg-Arg-Lys-Lys-Trp-
Trp。
The present invention provides the application that above-mentioned cell-penetrating peptide is delivered in cell in mediated adriablastina.
Above-mentioned cell is preferably tumour cell, most preferably cervical carcinoma, liver cancer or lung carcinoma cell.
Preferably, the cell-penetrating peptide can be combined with each other with adriamycin noncovalent interaction and mediated adriablastina delivering
Into cell.
Preferably, the cell-penetrating peptide mediated adriablastina delivering is the diagnosing and treating purpose of non-disease.
The present invention provides above-mentioned cell-penetrating peptide and is preparing the application in the drug that mediated adriablastina is delivered in cell.
Cell-penetrating peptide of the present invention can either load adriamycin by noncovalent interaction, and can efficiently mediated adriablastina delivering
To intracellular.
Compared with prior art, the present invention the nontoxic non-immunogenicity of the cell-penetrating peptide.And Solid-phase synthesis peptides technology maturation, it is honest and clean
Valence is easy to get, and manages convenient for quality.
Specific embodiment
Embodiment below facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiments
Method is unless otherwise specified conventional method.Test material as used in the following examples is unless otherwise specified city
It sells.
The synthesis of 1 cell-penetrating peptide of embodiment
1) activated resin: weighing 1000mg Fmoc-Trp wang Resin, and 30mL DMF is added and impregnates 30min, makes it
Sufficiently swelling.
2) it is deprotected: filtering the 30mL DMF for removing and impregnating resin, be added molten containing the DMF that mass percent is 20% piperidines
Liquid 30mL, nitrogen blow boiling 25min, then filter and remove, and with 10mL isopropanol and DMF, alternately washing resin three times, then uses indenes
Triketone method detects resin, and resin should be at black or purple.
3) condensation reaction: connecting next amino acid, the Fmoc- amino acid of 1.4mmol/g resin is weighed, with TBTU/
The 30mL DMF of HOBt/DIEA is reaction solution, and nitrogen blows boiling reaction 2h at room temperature.After reaction, replaced with 10mL isopropanol and DMF
Wash resin three times.Detect amino.
4) step 2) -3 is repeated) process: the sequence for pressing polypeptide extends polypeptide from C-terminal to N-terminal.Polypeptide sequence are as follows: Arg-
Arg-Lys-Lys-Trp-Trp。
5) polypeptide is cut: polypeptide-resin complexes is dried up with nitrogen, by TFA/phenol/ ultrapure water/
The ratio of thioanisole/EDT/TIS (80/5/5/5/3/2) is made into 30mL and mixes cutting reagent.Peptide resin is placed in round bottom
In flask, cutting liquid magnetic agitation 2h is added, sand core filter removes resin, and filtrate directly instills in chilled ethyl ether, 5000r/
Min centrifugation, freeze-drying is to constant weight up to thick peptide.
6) thick peptide is purified with HPLC, and purification condition is acetonihile gradient elution 30 minutes of 10% to 100%, and product purity is
97%.Obtain polypeptide after purification, polypeptide sequence are as follows: Arg-Arg-Lys-Lys-Trp-Trp.
2 cytotoxicity experiment of embodiment
1) 48 orifice plates are taken, every hole, which is added, contains 5 × 104A cervical cancer Hela cells culture solution, 37 DEG C, 5% carbon dioxide
Incubator 24 hours adherent to cell.
2) culture medium for configuring the cell-penetrating peptide of the concentration containing 1mM, using the culture medium of no cell-penetrating peptide as negative control hole
(Control), 37 DEG C, 5% carbon dioxide culture 48h.Culture medium prescription are as follows: the DMEM culture medium containing 10% fetal calf serum.
3) 20 μ l MTT are added in the every hole of attached cell, continue to discard culture solution after being incubated for 4h, 150 μ l are added in every hole
DMSO vibrates 10min.
4) 490nm wavelength is selected, cell survival rate is calculated by absorbance value in microplate reader immune detector.
1 cell-penetrating peptide toxotest of table
As shown in Table 1, (48h) is cultivated to cell survival cell-penetrating peptide of the invention for a long time under the conditions of high concentration (1mM)
Rate has not significant impact, and cell-penetrating peptide is safe and non-toxic.
3 cell-penetrating peptide of embodiment wears film and fluorescence detection experiment
1) culture medium of the cell-penetrating peptide containing a certain concentration FITC and FITC fluorescent marker is added in attached cell, is incubated for
Culture medium is carefully sucked after 30min-4h, and PBS washing attached cell is three times.Culture medium prescription are as follows: the DMEM containing 10% is cultivated
Base.
2) pancreatin reaction 5min is added to float to cell, adds fresh culture stopped reaction.
3) fluorescence volume that 10000 cells have is measured in flow cytometer.It is control and reference with FITC
(100%).
The delivering test of 2 multifunctional polypeptide mediated adriablastina of table
As shown in Table 2, FITC fluorescent marker cell-penetrating peptide group total fluorescence volume intracellular has the growth of the geometry order of magnitude compared with FITC group, this
The cell-penetrating peptide of invention efficiently wears film.
Embodiment 4 mediates cell-penetrating peptide delivery experiment
1) it is added and is incubated for cervical cancer Hela cells containing 5 mg/ml adriamycins and the culture medium of 0.1mM cell-penetrating peptide, incubate
Culture medium is carefully sucked after educating 30min, and PBS washing attached cell is three times.With the culture only containing 5 mg/ml adriamycins
Base is as control.Culture medium prescription are as follows: the DMEM culture medium containing 10% fetal calf serum.
2) Fresh cell culture medium culture is added for 24 hours.
3) 150 μ l DMSO are added in Hela cell per well, shake 10000rpm centrifuging and taking supernatant after 10min, obtain extraction intracellular
Liquid.
4) HPLC measures extracting solution doxorubicin concentration intracellular.As a result using adriamycin control group as reference (100%).
The delivering test of 3 multifunctional polypeptide mediated adriablastina of table
As shown in Table 3, multifunctional polypeptide of the invention can efficiently mediated adriablastina be delivered into the cell, corresponding adriamycin
Concentration is adriamycin control group 2 times or more.
Embodiment 5 mediates cell-penetrating peptide delivery experiment
1) it is added and is incubated for liver cancer cells containing 5 mg/ml adriamycins and the culture medium of 0.01mM cell-penetrating peptide, be incubated for
Culture medium is carefully sucked after 30min, and PBS washing attached cell is three times.With the culture medium only containing 5 mg/ml adriamycins
As control.Culture medium prescription are as follows: the DMEM culture medium containing 10% fetal calf serum.
2) Fresh cell culture medium culture is added for 24 hours.
3) 150 μ l DMSO are added in Hela cell per well, shake 10000rpm centrifuging and taking supernatant after 10min, obtain extraction intracellular
Liquid.
4) HPLC measures extracting solution doxorubicin concentration intracellular.As a result using adriamycin control group as reference (100%).
The delivering test of 4 multifunctional polypeptide mediated adriablastina of table
As shown in Table 4, multifunctional polypeptide of the invention can efficiently mediated adriablastina be delivered into the cell, corresponding adriamycin
Concentration is 1.3 times of adriamycin control group or more.
Embodiment 6 mediates cell-penetrating peptide delivery experiment
1) it is added and is incubated for lung carcinoma cell containing 5 mg/ml adriamycins and the culture medium of 0.05mM cell-penetrating peptide, be incubated for
Culture medium is carefully sucked after 30min, and PBS washing attached cell is three times.With the culture medium only containing 5 mg/ml adriamycins
As control.Culture medium prescription are as follows: the DMEM culture medium containing 10% fetal calf serum.
2) Fresh cell culture medium culture is added for 24 hours.
3) 150 μ l DMSO are added in Hela cell per well, shake 10000rpm centrifuging and taking supernatant after 10min, obtain extraction intracellular
Liquid.
4) HPLC measures extracting solution doxorubicin concentration intracellular.As a result using adriamycin control group as reference (100%).
The delivering test of 5 multifunctional polypeptide mediated adriablastina of table
As shown in Table 5, multifunctional polypeptide of the invention can efficiently mediated adriablastina be delivered into the cell, corresponding adriamycin
Concentration is 1.7 times of adriamycin control group or more.
Finally, it should be noted that the foregoing is only a preferred embodiment of the present invention, it is not intended to restrict the invention,
Although the present invention is described in detail referring to the foregoing embodiments, for those skilled in the art, still may be used
To modify the technical solutions described in the foregoing embodiments or equivalent replacement of some of the technical features.
All within the spirits and principles of the present invention, any modification, equivalent replacement, improvement and so on should be included in of the invention
Within protection scope.
Sequence table
<110>Nanyang Normal College
<120>a kind of cell-penetrating peptide and its application
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 6
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 1
Arg Arg Lys Lys Trp Trp
1 5
Claims (5)
1. a kind of cell-penetrating peptide, it is characterised in that: the amino acid sequence of the cell-penetrating peptide are as follows: Arg-Arg-Lys-Lys-Trp-Trp.
2. cell-penetrating peptide described in claim 1 is delivered to the application in cell in mediated adriablastina.
3. application according to claim 2, it is characterised in that: the cell-penetrating peptide can be mutual with adriamycin noncovalent interaction
In conjunction with, and energy mediated adriablastina is delivered in cell.
4. application according to claim 2 or 3, it is characterised in that: the cell-penetrating peptide mediated adriablastina delivering is non-disease
Diagnosing and treating purpose.
5. cell-penetrating peptide described in claim 1 is preparing the application in the drug that mediated adriablastina is delivered in cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811312090.2A CN109608519B (en) | 2018-11-06 | 2018-11-06 | Cell-penetrating peptide and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811312090.2A CN109608519B (en) | 2018-11-06 | 2018-11-06 | Cell-penetrating peptide and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109608519A true CN109608519A (en) | 2019-04-12 |
| CN109608519B CN109608519B (en) | 2022-06-10 |
Family
ID=66003097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811312090.2A Active CN109608519B (en) | 2018-11-06 | 2018-11-06 | Cell-penetrating peptide and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109608519B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110790821A (en) * | 2019-11-19 | 2020-02-14 | 南阳师范学院 | Cell nucleus penetrating peptide and application thereof |
| CN110845577A (en) * | 2019-11-19 | 2020-02-28 | 南阳师范学院 | Cell rapid cell-penetrating peptide and application thereof |
| CN114835775A (en) * | 2022-02-24 | 2022-08-02 | 南阳师范学院 | Novel cell-penetrating peptide and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104140457A (en) * | 2013-05-08 | 2014-11-12 | 浙江日升昌药业有限公司 | Tumor cell targeting penetrating peptide |
| CN107417769A (en) * | 2016-05-19 | 2017-12-01 | 中国科学院过程工程研究所 | A kind of novel cell-penetrating peptide of mediate drug delivering and its application |
| CN107987129A (en) * | 2017-12-25 | 2018-05-04 | 肽泽（武汉）生物科技有限公司 | A kind of cell-penetrating peptide and preparation method thereof, application |
-
2018
- 2018-11-06 CN CN201811312090.2A patent/CN109608519B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104140457A (en) * | 2013-05-08 | 2014-11-12 | 浙江日升昌药业有限公司 | Tumor cell targeting penetrating peptide |
| CN107417769A (en) * | 2016-05-19 | 2017-12-01 | 中国科学院过程工程研究所 | A kind of novel cell-penetrating peptide of mediate drug delivering and its application |
| CN107987129A (en) * | 2017-12-25 | 2018-05-04 | 肽泽（武汉）生物科技有限公司 | A kind of cell-penetrating peptide and preparation method thereof, application |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110790821A (en) * | 2019-11-19 | 2020-02-14 | 南阳师范学院 | Cell nucleus penetrating peptide and application thereof |
| CN110845577A (en) * | 2019-11-19 | 2020-02-28 | 南阳师范学院 | Cell rapid cell-penetrating peptide and application thereof |
| CN110845577B (en) * | 2019-11-19 | 2022-07-12 | 南阳师范学院 | Cell rapid cell-penetrating peptide and application thereof |
| CN110790821B (en) * | 2019-11-19 | 2022-09-02 | 南阳师范学院 | Cell nucleus penetrating peptide and application thereof |
| CN114835775A (en) * | 2022-02-24 | 2022-08-02 | 南阳师范学院 | Novel cell-penetrating peptide and application thereof |
| CN114835775B (en) * | 2022-02-24 | 2023-09-19 | 南阳师范学院 | Cell membrane penetrating peptide and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109608519B (en) | 2022-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109608519A (en) | A kind of cell-penetrating peptide and its application | |
| CN103172701B (en) | A kind of novel cell-penetrating peptide and application thereof | |
| Kuczer et al. | Studies of insect peptides alloferon, Any‐GS and their analogues. Synthesis and antiherpes activity | |
| Yang et al. | Design, synthesis and biological evaluation of novel peptide MC2 analogues from Momordica charantia as potential anti-diabetic agents | |
| CN103304637A (en) | Cell permeable peptide hPP3 and usage thereof | |
| CN107417769A (en) | A kind of novel cell-penetrating peptide of mediate drug delivering and its application | |
| CN102250254A (en) | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) fusion protein, its preparation and applications | |
| US20190100557A1 (en) | Protransduzin b, a gene transfer enhancer | |
| CN107474117B (en) | Antitumor cyclopeptide and preparation method and medical application thereof | |
| KR101444199B1 (en) | Cell Penetrating Peptides and Use thereof | |
| CN105504063B (en) | The antineoplastic amalgamation protein of a kind of alexin-albumin and its preparation and application | |
| CN104193826B (en) | A kind of fused polypeptide and its application in antineoplastic is prepared | |
| KR101135460B1 (en) | Cell penetrating peptides and use thereof | |
| CN110845577B (en) | Cell rapid cell-penetrating peptide and application thereof | |
| CN109999202A (en) | It is a kind of mediate taxol delivering multifunctional polypeptide and its application | |
| CN110669145B (en) | Method for modifying mesenchymal stem cells by tripolymer TRAIL fusion protein gene and application thereof | |
| CN110790821B (en) | Cell nucleus penetrating peptide and application thereof | |
| Jiang et al. | A dimethylbromobenzene-cysteine stapled peptide dual inhibitor of the p53-MDM2/MDMX interactions | |
| JP4831410B2 (en) | Antiviral peptides and antiviral agents | |
| CN107098963B (en) | Short peptide for inhibiting tumor and coding gene and application thereof | |
| CN102199608B (en) | Efficient expression of pinellia ternate agglutinin (PTA) in bombyx mori reactor | |
| KR101444197B1 (en) | Cell Penetrating Peptides and Use thereof | |
| CN106110297B (en) | Application of GFI1 truncated body | |
| CN114835775B (en) | Cell membrane penetrating peptide and application thereof | |
| CN113773370B (en) | Antiviral polypeptide and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |